BICO introduces new life sciences manufacturing platform integrating ABB Robotics technology
BICO Group’s business area Bioautomation is expanding its manufacturing product offering by introducing The Nucleus™ Automation Ecosystem, a fully integrated platform bringing a new level of modularity, flexibility and scalability to the manufacturing market.
Designed with the support of industry leader ABB Robotics, The Nucleus™ reduces time and costs by a seamless transition from R&D through to manufacturing, due to unique modularity while utilizing knowledge and validation though the scale up phases. The first prototype will be showcased at SLAS International Conference and Exhibition (February 24th- March 1st), as a part of the SCIENION`s sciFLEXARRAYER manufacturing solutions.www.scienion.comAbout ABB ABB Robotics & Discrete Automation as one of the world’s leading robotics and machine automation suppliers, is the only company with a comprehensive and integrated portfolio covering robots, Autonomous Mobile Robots and machine automation solutions, designed and orchestrated by our value-creating software. We help companies of all sizes and sectors – from automotive to electronics and logistics – become more resilient, flexible and efficient. ABB Robotics & Discrete Automation supports customers in the transition towards the connected and collaborative factory of the future. The business area employs approximately 11,000 people at over 100 locations in approximately 53 countries.go.abb/robotics.http://www.abb.com/Supporting the complete application envelope, The Nucleus™ utilizes core precise material handling – regardless of the substrate type, dedicated environmental control specific to process steps, through to pick and place and packaging. Process steps include, but are not limited to, RFID readouts, quality control stations, cloud storage, laser welding, drying, and pouching operations. The Nucleus™ ensures precise motion control and real-time analysis, including individual tracing of devices. Additionally, the process steps are housed in the same enclosure, thus reducing the overall footprint of the system, as well as facility utilities for the manufacturing space. Coupled with SCIENION’s precision dispense technologies enables a platform to deliver a dynamic dispense range from picoliter to nanoliter volumes in a fully controlled environment. Dr. Holger Eickhoff, Co-founder and Co-CEO of SCIENION, said “We are delighted to expand our manufacturing solutions to the marketplace with proven suppliers. We have seen a dynamic increase in our customers’ scale up requirements, and The Nucleus™ allows us to support the entire application from precise material handling, environmental control specific to each step, through to packaging. Moreover, this will give our customer access to the ABB Robotics service and support Worldwide”. Erik Gatenholm, President & CEO of BICO Group, “With the all-new Nucleus™ platform, our Bioautomation Business Area will continue to support our current customers while also transition into new market opportunities such as printing and manufacturing of medical devices, approaching higher end market segments and add value where the highest level of precision dispensing and automation is needed” About SCIENION SCIENION, a BICO company, is a renowned specialist in ultra-low volume precision liquid handling in the pico-liter to micro-liter range, enabling applications from research to high-throughput production of assays in diagnostics and life sciences. Addressing the dynamically increasing needs for miniaturization and multiplex analyses, SCIENION is an ISO 9001:2015 certified complete solution provider offering a unique portfolio of automated precision dispensing systems, readers, consumables, assay development and contract manufacturing services.
For further information, please contact:[email protected]Erik Gatenholm, President & CEO, BICO Group AB Email:
Holger Eickhoff, Co-CEO, Scienion GmbH[email protected]E-mail:
About BICOBICO is a leading provider of life science solutions and laboratory automation that enable more efficient development of new treatments with more specificity and less need for animal testing.
The company uses bioconvergence as its operating system, combining advanced technologies with biology to streamline and automate workflows within the pharmaceutical and biopharma industries.
With 32,000+ instruments installed in over 65 countries, BICO products and solutions are found in more than 3,500 laboratories, including the world’s top 20 pharmaceutical companies, and have been cited in over 11,000 publications.
Operating through three business areas – Bioprinting, Biosciences and Bioautomation – the BICO Group strives towards the long-term ambition of enabling the reduction the world’s organ shortage and speeding up drug development to create the future of life-saving treatments.
BICO is listed on Mid-Cap, Nasdaq Stockholm under BICO. www.bico.com